Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates manufactured at our MCAT facility in RTP and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist.

For more information about Precision BioSciences, please visit